Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

Fortunately, RSV illness is mild in otherwise healthy people. The market for RSV treatments currently has only one, narrowly defined patient group: prematurely born infants at high risk of ...

The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...

With millions of cases annually worldwide, especially among infants under six months, RSV imposes a significant burden on families and healthcare systems. Current treatments are limited to symptomatic ...

With millions of cases annually worldwide, especially among infants under six months, RSV imposes a significant burden on families and healthcare systems. Current treatments are limited to ...

Other conditions associated with higher rates of RSV hospitalization were functional dependence, asthma, severe obesity, diabetes and chronic kidney disease. People living in nursing homes were ...

"There's no specific treatment for an RSV infection," the NHS explains. "It often gets better on its own in one or two weeks and you can usually look after yourself or your child at home.